Filing Details
- Accession Number:
- 0001203311-20-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-05-12 19:51:56
- Reporting Period:
- 2020-05-08
- Accepted Time:
- 2020-05-12 19:51:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1060736 | Seattle Genetics Inc | SGEN | Biological Products, (No Disgnostic Substances) (2836) | 911874389 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1167496 | B Clay Siegall | 21823 30Th Drive Se Bothell WA 98021 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-05-08 | 10,264 | $12.00 | 728,603 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-08 | 10,264 | $160.02 | 718,339 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-05-08 | 8,204 | $12.00 | 726,543 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-08 | 8,204 | $160.72 | 718,339 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-05-08 | 5,355 | $12.00 | 723,694 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-08 | 5,355 | $161.74 | 718,339 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-05-08 | 3,549 | $12.00 | 721,888 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-08 | 3,549 | $162.68 | 718,339 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-05-08 | 1,100 | $12.00 | 719,439 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-05-08 | 1,100 | $163.50 | 718,339 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-05-08 | 10,264 | $0.00 | 10,264 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-05-08 | 8,204 | $0.00 | 8,204 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-05-08 | 5,355 | $0.00 | 5,355 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-05-08 | 3,549 | $0.00 | 3,549 | $12.00 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2020-05-08 | 1,100 | $0.00 | 1,100 | $12.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 103,627 | 2020-08-27 | No | 4 | M | Direct | |
| 95,423 | 2020-08-27 | No | 4 | M | Direct | |
| 90,068 | 2020-08-27 | No | 4 | M | Direct | |
| 86,519 | 2020-08-27 | No | 4 | M | Direct | |
| 85,419 | 2020-08-27 | No | 4 | M | Direct |
Footnotes
- Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $159.35 to $160.34 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $160.35 to $161.34. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $161.35 to $162.34. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $162.36 to $163.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Reflects sales of common stock executed in multiple transactions at prices ranging from $163.38 to $163.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- Options vested at a rate of 25% on 8/27/11 and monthly thereafter until all the shares were fully vested on 8/27/14.
Billionaire Hedge Funds
